DeepMed Research

Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Phase 3

Completed

Conditions: Fatigue
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic/Myeloproliferative Neoplasms
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Unspecified Adult Solid Tumor, Protocol Specific
Precancerous Condition

Interventions: Drug: American ginseng
Other: placebo

First Posted Date: 2008-07-21

Last Posted Date: 2017-02-09

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 364

Registration Number: NCT00719563

Locations: 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸
Illinois CancerCare - Havana, Havana, Illinois, United States
🇺🇸
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States

and more 319 locations

Pregabalin in Treating Women With Hot Flashes

Phase 3

Completed

Conditions: Breast Cancer
Hot Flashes

Interventions: Drug: pregabalin
Other: placebo

First Posted Date: 2008-06-20

Last Posted Date: 2016-08-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 207

Registration Number: NCT00702949

Locations: 🇺🇸
Galesburg Clinic, PC, Galesburg, Illinois, United States
🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸
McDonough District Hospital, Macomb, Illinois, United States

and more 204 locations

Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: bevacizumab
Drug: gemcitabine hydrochloride
Drug: paclitaxel albumin-stabilized nanoparticle formulation

First Posted Date: 2008-04-21

Last Posted Date: 2017-04-17

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 50

Registration Number: NCT00662129

Locations: 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States
🇺🇸
St. Mary Mercy Hospital, Livonia, Michigan, United States

and more 88 locations

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Conditions: Leukemia

Interventions: Drug: cytarabine
Drug: daunorubicin
Other: placebo
Drug: midostaurin
Drug: dexamethasone acetate

First Posted Date: 2008-04-02

Last Posted Date: 2021-08-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 717

Registration Number: NCT00651261

Locations: 🇺🇸
St. Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸
Ministry Saint Clare's Hospital, Weston, Wisconsin, United States
🇺🇸
Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States

and more 173 locations

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Phase 3

Active, not recruiting

Conditions: Lung Cancer

Interventions: Radiation: Standard Radiation Dose Therapy
Drug: cisplatin
Drug: etoposide
Radiation: High Radiation Dose Therapy
Drug: carboplatin

First Posted Date: 2008-03-11

Last Posted Date: 2023-06-12

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 731

Registration Number: NCT00632853

Locations: 🇺🇸
Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸
NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States
🇺🇸
Illinois CancerCare-Princeton, Princeton, Illinois, United States

and more 928 locations

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: bevacizumab
Drug: temozolomide
Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation

First Posted Date: 2008-02-29

Last Posted Date: 2018-05-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 95

Registration Number: NCT00626405

Locations: 🇺🇸
Swedish Medical Center, Englewood, Colorado, United States
🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸
St. James Healthcare Cancer Care, Butte, Montana, United States

and more 252 locations

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Biological: bevacizumab
Drug: sorafenib tosylate

First Posted Date: 2008-02-22

Last Posted Date: 2018-05-08

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 54

Registration Number: NCT00621686

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Cancer Care Associates, Fresno, California, United States
🇺🇸
Front Range Cancer Specialists, Fort Collins, Colorado, United States

and more 199 locations

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: panitumumab
Drug: capecitabine
Drug: fluorouracil
Drug: gemcitabine hydrochloride
Radiation: radiation therapy

First Posted Date: 2008-01-28

Last Posted Date: 2017-04-05

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 52

Registration Number: NCT00601627

Locations: 🇺🇸
Great Falls Clinic - Main Facility, Great Falls, Montana, United States
🇺🇸
Mid Dakota Clinic, PC, Bismarck, North Dakota, United States
🇺🇸
Illinois CancerCare - Canton, Canton, Illinois, United States

and more 274 locations

Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: cediranib maleate
Drug: irinotecan hydrochloride

First Posted Date: 2008-01-09

Last Posted Date: 2017-04-05

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 5

Registration Number: NCT00588900

Locations: 🇺🇸
Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

and more 28 locations

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Biological: cetuximab
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2007-12-12

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT00571740

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy